Page last updated: 2024-10-25

ciprofloxacin and Epidermolysis Bullosa

ciprofloxacin has been researched along with Epidermolysis Bullosa in 1 studies

Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.

Epidermolysis Bullosa: Group of genetically determined disorders characterized by the blistering of skin and mucosae. There are four major forms: acquired, simple, junctional, and dystrophic. Each of the latter three has several varieties.

Research Excerpts

ExcerptRelevanceReference
"Ciprofloxacin-resistant SA was found significantly predominant in chronic wounds (**P < ."1.91Longitudinal study of wound healing status and bacterial colonisation of Staphylococcus aureus and Corynebacterium diphtheriae in epidermolysis bullosa patients. ( Acevedo, F; Arancibia, E; Fuentes, I; Morandé, P; Oróstica, K; Palisson, F; Porte, L; Rebolledo-Jaramillo, B; Varela, C; Yubero, MJ, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Fuentes, I1
Yubero, MJ1
Morandé, P1
Varela, C1
Oróstica, K1
Acevedo, F1
Rebolledo-Jaramillo, B1
Arancibia, E1
Porte, L1
Palisson, F1

Other Studies

1 other study available for ciprofloxacin and Epidermolysis Bullosa

ArticleYear
Longitudinal study of wound healing status and bacterial colonisation of Staphylococcus aureus and Corynebacterium diphtheriae in epidermolysis bullosa patients.
    International wound journal, 2023, Volume: 20, Issue:3

    Topics: Ciprofloxacin; Corynebacterium diphtheriae; Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica

2023